Literature DB >> 25857384

Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.

Valeria Ascoli.   

Abstract

Malignant mesothelioma (MM) is rare and difficult to diagnose. Its identification depends upon pathological investigation (cyto-histological assessment and immunohistochemistry) supported by clinical and radiological evidence. In the last decade, the standardization of diagnostic methods has become a major focus of debate among pathologists and clinicians. This has led to the writing of guidelines and recommendation for the diagnosis to achieve the goal of a standard diagnosis. In this article, a chronological view relating to the pathological diagnosis of MM is presented together with a review of guidelines and recommendations.

Entities:  

Mesh:

Year:  2015        PMID: 25857384     DOI: 10.4415/ANN_15_01_09

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  6 in total

1.  The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.

Authors:  Nurhan Sahin; Ayse Nur Akatli; Muhammet Reha Celik; Hakkı Ulutas; Emine Turkmen Samdanci; Cemil Colak
Journal:  Pathol Oncol Res       Date:  2016-10-19       Impact factor: 3.201

Review 2.  CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Authors:  Lourdes Cortes-Dericks; Ralph Alexander Schmid
Journal:  Respir Res       Date:  2017-04-12

3.  Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.

Authors:  Lukas Jyuhn-Hsiarn Lee; Cheng-Kuan Lin; Chih-Hong Pan; Yawen Cheng; Yu-Yin Chang; Saou-Hsing Liou; Jung-Der Wang
Journal:  BMJ Open       Date:  2018-12-09       Impact factor: 2.692

4.  Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database.

Authors:  Asad Ullah; Abdul Waheed; Jaffar Khan; Ankita Mishra; Bisma Tareen; Noor Nama; Nabin Raj Karki; Muhammad Saleem Panezai; Luis Velasquez Zarate; Joseph White; Frederick D Cason; Nathaniel Matolo; Subhasis Misra; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

5.  Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications.

Authors:  Marcelo Luiz Balancin; Camila Machado Baldavira; Tabatha Gutierrez Prieto; Juliana Machado-Rugolo; Cecília Farhat; Aline Kawassaki Assato; Ana Paula Pereira Velosa; Walcy Rosolia Teodoro; Alexandre Muxfeldt Ab'Saber; Teresa Yae Takagaki; Vera Luiza Capelozzi
Journal:  Front Med (Lausanne)       Date:  2022-04-13

6.  An integrative histopathologic clustering model based on immuno-matrix elements to predict the risk of death in malignant mesothelioma.

Authors:  Marcelo Luiz Balancin; Walcy Rosolia Teodoro; Cecilia Farhat; Tomas Jurandir de Miranda; Aline Kawassaki Assato; Neila Aparecida de Souza Silva; Ana Paula Velosa; Roberto Falzoni; Alexandre Muxfeldt Ab'Saber; Anja C Roden; Vera Luiza Capelozzi
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.